- In a regulatory 8-K filing, on June 30, Dare Bioscience Inc DARE entered into an agreement with the Bill & Melinda Gates Foundation for a new grant of up to $48.95 million for DARE-LARC1, its investigational user-controlled, long-acting reversible contraceptive.
- The Grant will support technology development and preclinical activities to advance DARE-LARC1 toward clinical testing in humans from June 30 to November 1, 2026.
- The company will receive an initial payment of $11.45 million in July 2021.
- Additional payments are contingent upon the DARE-LARC1 program's achievement of specified milestones.
- Price Action: DARE shares are up 23.4% at $1.87 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
